- Treatment information · For patients considering the programme

Three licensed treatments. One programme.

Information for patients already considering MediPill’s pharmacist-led weight-management programme. Final prescribing decisions are made only in a live consultation with a UK-registered pharmacist, in branch or by video. The content below is reference material for those weighing up the programme – not an offer to supply medication.

- Interactive · Based on STEP-1 & SURMOUNT-1 trial data

See a projection.

Enter your starting weight and choose a treatment to see the average 12-month outcome reported in pivotal clinical trials. Individual results vary.

12–15%

Average weight loss reported on Wegovy at one year – STEP-1 trial

20%

Average weight loss reported on Mounjaro – SURMOUNT-1 trial, the highest of any approved medication

1 working day

Typical pharmacist callback after you submit the pre-screening form

- Wegovy · Wegovy (oral) · Mounjaro

Three MHRA-licensed treatments. One programme.

Two weekly injectables and a once-daily tablet – the three MHRA-licensed medication options used for weight management in the UK. Your pharmacist will match you to the appropriate option, if eligible, based on your health profile, tolerance and goals.

Wegovy

Semaglutide. GLP-1 receptor agonist that mimics a gut hormone – slows stomach emptying and reduces appetite. Weekly subcutaneous injection. Longer real-world data and a slightly milder side-effect profile than Mounjaro.

Indicative doses & cost per month

Dose	Per month
0.25mg starting	£150
0.5mg	£180
1mg	£200
1.7mg	£250
2.4mg maintenance	£270

Average loss at 52 weeks · STEP-1

0 %

Wegovy (oral)

Oral semaglutide. The same active ingredient as the Wegovy injection, in a once-daily tablet – the first GLP-1 weight-loss pill licensed by the MHRA. Taken on an empty stomach, 30 minutes before food. Needle-free.

Indicative doses & cost per month

Dose	Per month
1.5mg starting	£129
4mg	£149
9mg	£189
25mg maintenance	£229

Your dose is confirmed at your clinical assessment.

Average loss at 64 weeks · OASIS-4 · 25mg tablet

0 .6%

Mounjaro

Tirzepatide. Dual GIP and GLP-1 receptor agonist – the only approved dual-action injectable for weight management. Higher average weight loss in clinical trials than any other licensed medication. Weekly subcutaneous injection.

Indicative doses & cost per month

Dose	Per month
2.5mg starting	£210
5mg	£225
7.5mg	£270
10mg	£300
12.5mg	£315
15mg maintenance	£335

Average loss at 72 weeks · SURMOUNT-1

0 %

- Clinical evidence

Real-world numbers from real trials.

Average loss at 40 weeks · Wegovy STEP-1 · 1961 adults

0 %

Average loss at 52 weeks · Sustained Wegovy programme

0 %

Average loss at 72 weeks · Mounjaro SURMOUNT-1 · highest of any approved medication

0 %

- Safety

Side effects, titration and stopping.

What are the common side effects?

Nausea, mild diarrhoea or constipation, and fatigue are the most common, particularly in the first few weeks while the dose is escalating. Most settle within 4–6 weeks. We titrate slowly to minimise impact – that’s a big part of the monthly review.

Who isn’t a candidate?

These medications are not appropriate for everyone. Pregnancy, breastfeeding, personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN-2), severe gastroparesis, and certain pancreatic conditions are full contraindications. Several other conditions require caution. Your pharmacist works through this in detail at your consultation.

How fast does titration go?

Both medications are designed to be titrated upward over several months. We escalate at the speed your body can handle, not on a fixed schedule. Most patients reach a stable maintenance dose within 3–5 months.

What about stopping?

Most patients stay on treatment for 12–24 months. Abrupt stopping is associated with weight regain, so we talk through a step-down plan together when you’re close to your goal. The monthly review is where this decision happens – it isn’t a fixed protocol.

Why monthly reviews?

Both medications are real clinical interventions with real side effects and dose decisions that change every few weeks. A monthly review, in branch or by video, lets your pharmacist check your progress, side-effect profile and overall wellbeing – and adjust the plan in real time.

Is this on the NHS?

NHS access is currently limited and gated by tier-3 specialist clinics with very long waits. Private prescription via a live pharmacist consultation, in branch or by video, gives same-day decisions after your initial 45-minute consult. Cost is your medication plus the consultation fee only – no extra subscription.

- Pharmacist-led safety

Every dose decision is made with your pharmacist.Titration is monitored at every monthly review – never on a fixed schedule. Contraindications are checked in detail at your initial 45-minute consultation. The same pharmacist sees you throughout, and supports a structured step-down plan when you reach your goal.

✓ The same pharmacist sees you at every visit✓ Dose increases move at your pace – never a fixed schedule✓ Full contraindication check before anything is prescribed

- Ready to begin?

Eligibility is decided by your pharmacist.

If you’ve read this far you’re considering the programme seriously. The next step is the pre-screening form – a pharmacist will call you within one working day to arrange your 45-minute consultation, in branch or by video.

Prefer to talk it through by video? A 45-minute video consultation with a pharmacist costs £40, paid when you book (refunded in full if you cancel more than 24 hours before, and not deducted from your treatment). Collect your medicine in person from the MediPill branch you choose. Have photo ID, bathroom scales and a tape measure ready for the call.